N-methyl-D-aspartate receptor and P2Y purinoceptor 12 (NMDAR + P2Y12R)

The N-methyl-D-aspartate (NMDA) receptor and P2Y purinoceptor 12 (P2Y12) represent a critical functional axis in the central nervous system, particularly in the context of neuroinflammation and excitotoxicity (Dissing-Olesen et al., 2014; Eyo et al., 2014). The NMDA receptor is a ligand-gated ionotropic glutamate receptor essential for synaptic plasticity and memory, though its overactivation leads to calcium-mediated neuronal death (StatPearls, 2023). The P2Y12 receptor is a G protein-coupled receptor primarily known for its role in platelet aggregation and microglial motility (MDPI, 2021). Research has demonstrated that neuronal NMDA receptor activity recruits microglial processes via P2Y12 receptor activation, a mechanism that appears to be neuroprotective in conditions like epilepsy and stroke (Journal of Neuroscience, 2014). Drugs targeting these receptors individually, such as memantine for Alzheimer's disease and clopidogrel for cardiovascular events, are well-established, and their combined functional modulation is an area of active research for treating complex neurological disorders (Frontiers, 2021).

Other names

NMDA receptor and P2Y12 receptorNMDAR-P2Y12R axisGlutamate [NMDA] receptor and Purinergic P2Y12 receptor

The NMDA receptor is an ionotropic glutamate receptor that mediates excitatory neurotransmission and calcium influx, while the P2Y12 receptor is a G protein-coupled receptor that mediates platelet aggregation and microglial chemotaxis. In the central nervous system, neuronal NMDA receptor activation triggers the release of ATP, which is metabolized to ADP and subsequently activates microglial P2Y12 receptors, facilitating neuroprotective microglial-neuronal interactions and process extension toward hyperactive neurons.